Annual Cancer Report Indicates Rapid Decrease in Deaths From Lung Cancer and Melanoma

Article

This year’s Annual Report to the Nation on the Status of Cancer highlights trends in cancer incidence and mortality overall and in key patient subgroups.

Cancer mortality rates are declining in men and women across all racial and ethnic groups, with notable declines in lung cancer and metastatic melanoma deaths noted from 2001 to 2018, according to the most recent Annual Report to the Nation on the Status of Cancer.1 That said, several other tumor types that were previously experiencing declining death rates, including prostate, colorectal (CRC), and female breast cancer, have either experienced a slowing or halt of decline entirely.

Among some of the more favorable trends, lung cancer death rates per year were found to have particularly declined for men, dropping 2.0% per year from 2001 to 2005, 2.9% from 2005 to 2012, 4.0% from 2012 to 2015, and 5.7% from 2015 to 2018.2 Mortality rates for kidney cancer have also been on the decline since 2001 in both sexes, although it began declining more rapidly for men in 2015. After a period of stable trends, melanoma death rates began a notable decline in 2013 for male patients (5.7% per year) and in 2012 for female patients (4.4% per year). Additionally, bladder cancer mortality began to fall in 2013 for men (1.3% per year) with a steady decrease for women from 2001 to 2018 (0.6% per year). Liver cancer mortality stabilized for men and decelerated for women from 2013 to 2018.

“The declines in lung cancer and melanoma death rates are the result of progress across the entire cancer continuum—from reduced smoking rates to prevent cancer to discoveries such as targeted drug therapies and immune checkpoint inhibitors,” Karen E. Knudsen, MBA, PhD, chief executive officer of the American Cancer Society, said in a press release. “While we celebrate the progress, we must remain committed to research, patient support, and advocacy to make even greater progress to improve the lives of patients [with cancer] and their families.”

By contrast, while female breast cancer death rates decreased by 2.3% per year on average during 2003 to 2007, it decreased by 1.6% per year for 2007 through 2014 and 1.0% for 2014 to 2018. Similarly, prostate cancer death rates decreased by 3.5% per year on average from 2001 to 2013 and stabilized from 2013 to 2018.

The report, which covers a period prior to the COVID-19 pandemic, also found that overall incidence rates of cancer had decreased overall among women, children, and adolescents and young adults. Overall, the report observed a decrease in death rates for 11 of the 19 most common cancers for men and 14 of the 20 most common cancers for women during 2014 to 2018.

Long-term trends in cancer mortality rates in the annual report indicated that the decline in death rate accelerated for both male and female patients from 2001 to 2018. Male patients experienced a 1.8% decline in mortality per year from 2001 to 2015, which increased to 2.3% per year from 2015 to 2018. Moreover, female patients experienced a decline of 1.4% per year from 2001 to 2015, which increased to 2.1% per year from 2015 to 2018.

Cancer death rates were highest among Black populations (182.5 per 100,000) followed byAmerican Indian/Alaska Native (163.2 per 100,000), White (160.2 per 100,000), Hispanic (110.8 per 100,000), and Asian/Pacific Islanders (98.0 per 100,000). Although prostate cancer deaths were stable among White, Black, and Hispanic men, rates decreased for Asian/Pacific Islanders and American Indian/Alaska Natives. Moreover, CRC death rates declined among all racial and ethnic groups with the exception of American Indian/Alaska Natives who experienced stable rates. In pancreatic cancer—the fourth most common cancer-related death among White and Black men—mortality rates increased for White men but was stable for all other groups.

TABLE: Cancer Mortality by Race (Per 100,000)

TABLE: Cancer Mortality by Race (Per 100,000)

Mortality rates for lung cancer, breast cancer, and CRC decreased for all female patients across all racial and ethnic groups from 2014 to 2018, with the exception stable rates observed in breast cancer deaths in Asian/Pacific Islanders and American Indian/Alaska Natives and CRC cancer deaths among American Indian/Alaska Natives. While pancreatic cancer death rates slightly increased for women, there was not a statistically significant increase in any one racial or ethnic group. Uterine cancer accounted for the largest increase in death rates for women during the 2014 to 2018 period, wherein increased rates were observed among White, Black, Asian/Pacific Islanders, and Hispanic females.

“It is encouraging to see a continued decline in death rates for many of the common cancers,” Karen Hacker, MD, MPH, director of Centers for Disease Control and Prevention’s National Center for Chronic Disease Prevention and Health Promotion, said in a press release. “To dismantle existing health disparities and give everyone the opportunity to be as healthy as possible, we must continue to find innovative ways to reach people across the cancer care continuum—from screening and early detection to treatment and support for survivors.”

Despite an increase in incidence during 2001 to 2017, cancer mortality rates are continuing to decline among children under the age of 15 and adolescents and young adults who are 15 to 39 years of age. Overall incidences of cancer increased in children and young adults and adolescents across all racial and ethnic groups, with the exception of American Indian/Alaska Natives whose rates remained stable. Among adolescents and young adults, the most common tumor type was female breast cancer.

“When evaluating health disparities, it is critical to acknowledge the social factors that influence the health of the communities and access to health care,” Betsy A. Kohler, MPH, Executive Director of North American Association of Central Cancer Registries, concluded. “Social and economic indicators, particularly based on small area assessments, are increasingly important to understanding the burden of cancer.”

References

  1. Annual report to the nation: rapid decrease in lung cancer and melanoma deaths. News release. American Cancer Society. July 8, 2021. Accessed July 9, 2021. https://bit.ly/36tF4Kx
  2. Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. J Natl Cancer Inst. Published online July 8, 2021. doi:10.1093/jnci/djab131.
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.